Author

M. Sadelain

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 5 Organism:human· 4 Research Focus:drug response / drug discovery· 3 Assay:proteomics· 3 Research Focus:cell type annotation· 2 Research Focus:host-pathogen & immune response· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1

Frequent Co-Authors

K.-J. Malmberg· 2 shared Q. Hammer· 2 shared A. S. Harris· 1 shared A. Williams· 1 shared B. Groff· 1 shared B. Onfelt· 1 shared B. Valamehr· 1 shared C. A. Klebanoff· 1 shared

Activity by Year

2022-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 18 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

K.-J. Malmberg

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Senolytic CAR T cells reverse aging-associated defects in intestinal regeneration and fitness

O. Eskiocak, S. Chowdhury, V. Shah, E. Nnuji-John, C. Chung, J. A. Boyer, A. S. Harris, J. Habel, M. Sadelain, S. Beyaz, C. Amor

This study shows that senolytic CAR T cells remove senescent cells in the aging gut, improving intestinal regeneration and immune function.

bioRxiv · Mar 19, 2024 · PreprintCell Biology

CAR-engineered lymphocyte persistence is governed by a FAS ligand/FAS auto-regulatory circuit

F. Yi, T. Cohen, N. Zimmerman, F. A. Dundar, P. Zumbo, R. Eltilib, E. J. Brophy, H. Arkin, J. Feucht, M. V. Gormally, C. S. Hackett, K. N. Kropp, I. Etxeberria, S. S. Chandran, J. H. Park, , C. A. Klebanoff

This study identifies FASLG expression patterns and shows that FAS-L/FAS auto-regulation governs CAR-T and CAR-NK cell persistence, enhancing antitumor efficacy when FAS is inhibited.

bioRxiv · Feb 26, 2024 · PreprintImmunology

Targeting HLA-E Positive Cancers with a Novel NKG2A/C Switch Receptor

M. L. Saetersmoen, I. Kotchetkov, L. Torralba-Raga, J. Masilla-Soto, E. Sohlberg, S. Z. Krokeide, Q. Hammer, M. Sadelain, K.-J. Malmberg

This paper develops a novel chimeric A/C switch receptor to target HLA-E positive cancers, showing enhanced anti-tumor activity while avoiding off-tumor toxicity.

bioRxiv · Dec 14, 2023 · PreprintImmunology

Genetic ablation of adhesion ligands averts rejection of allogeneic immune cells

Q. Hammer, K. Perica, H. van Ooijen, R. Mbofung, P. Momayyezi, E. Varady, K. E. Martin, Y. Pan, M. Jelcic, B. Groff, R. Abujarour, S. Krokeide, T. Lee, A. Williams, J. P. Goodridge, , K.-J. Malmberg

This study shows that deleting adhesion ligands CD54 and CD58 on allogeneic immune cells reduces NK cell rejection without impairing their anti-tumor activity.

bioRxiv · Oct 9, 2023 · PreprintImmunology

Balancing activation and costimulation of CAR tunes signaling dynamics and enhances therapeutic potency

J. Sun, Y. Duan, J. Chen, X. Meng, L. Liu, K. Shang, X. Wu, Y. Wang, Z. Huang, H. Liu, Y. Huang, C. Zhou, X. Gao, Y. Wang, M. Sadelain

This study shows that modifying CAR activation motifs improves anti-tumor efficacy in solid tumors despite reduced in vitro cytotoxicity.

bioRxiv · Mar 1, 2022Immunology